# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Oppenheimer analyst Jay Olson maintains Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $10 price target.
Wedbush analyst David Nierengarten reiterates Sutro Biopharma (NASDAQ:STRO) with a Outperform and maintains $8 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates Sutro Biopharma (NASDAQ:STRO) with a Buy and maintains $12 price target.
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0...
B of A Securities analyst Tazeen Ahmad initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces P...